Senior Physician Executive
About the job
- Significant experience as an MD, PA, or NP.
- A proven track record working in healthcare technology roles, such as Clinical Informatics, Enterprise Analytics, or Implementation Executive, demonstrating successful adoption and integration of clinical solutions.
- Ability to clearly communicate complex clinical and technical concepts to frontline clinicians, healthcare executives, and technical teams.
- Demonstrated experience and comfort engaging and influencing senior executives, including CNOs, CNIOs, CMIOs, CIOs, and CFOs.
- Ability to work cross-functionally, influence without direct authority, and serve as a trusted clinical advisor internally and externally.
- Ability to evaluate clinical workflows, identify opportunities for improvement, and translate clinical requirements into technological solutions.
- Serve as a clinical resource supporting sales and partner success teams by demonstrating how Abridge’s ambient solutions enhance clinical workflows and patient outcomes.
- Partner with commercial teams during demos, customer presentations, and strategic engagements, providing clinical credibility and subject matter expertise to executive-level audiences.
- Engage directly with prospective and current customers, including senior leadership, to articulate clinical value, address questions, and facilitate adoption.
- Provide insights and feedback from prospect interactions to the product and engineering teams, assisting in prioritizing product enhancements to align with clinical needs.
- Represent Abridge at industry conferences, webinars, and events as a clinical thought leader.
- Serve as the product expert for the commercial team and collaborate with the Product team to align customer needs, solution capabilities, and the product roadmap.
- Experience in clinical success, implementation leadership, clinical analytics, or similar roles within major health systems or healthcare technology companies, such as Epic.
- Ability to manage and lead teams or complex projects, ideally with experience in healthcare quality, analytics, and informatics initiatives.
About the company
Abridge builds AI software that listens to conversations between clinicians and patients and drafts the clinical notes doctors would otherwise type, mainly for large health systems. In 2024, Kaiser Permanente rolled it out across its hospitals and medical offices in what was then the largest generative AI deployment in health care. With the patient's consent, clinicians record the visit, and a structured note is ready in their electronic health record when it ends, with each part traceable to the transcript and audio. It also captures orders, billing codes, and patient summaries, and health systems pay for it through enterprise subscriptions. Abridge was founded in Pittsburgh in 2018 and is based in San Francisco.
Company Size
201-500
Company Stage
Series E
Total Funding
$757.5M
Headquarters
Pittsburgh, Pennsylvania
Founded
2018
Get referred to Abridge
See people who can refer or advise you
Simplify's Take
What believers are saying
- Customers keep signing on: Abridge grew from over 200 health systems in October 2025 to over 300 by June 2026.
- Government work adds stability: in September 2026, Veterans Affairs chose Abridge for a five-year, two-vendor contract capped at $775.7 million.
- Engineers are paid well: machine learning staff roles at Abridge list $205,000 to $300,000 a year plus equity.
What critics are saying
- Partner turned rival: Epic, the records system in 42% of US acute hospitals, launched AI note-taking in February 2026.
- Privacy suits follow its rollouts: in April 2026, patients sued Sutter Health and MemorialCare over allegedly unconsented Abridge recordings.
- Expect three office days a week: hybrid posts set that minimum, and 32 of 47 openings are in San Francisco.
What makes Abridge unique
- A practicing cardiologist runs it: CEO Shiv Rao takes on-call shifts on Thursdays and one weekend a month.
- Abridge and Microsoft lead AI note-taking: Abridge held 30% of 2025's $600 million market, Microsoft's Nuance unit 33%.
- A drugmaker is an owner: Eli Lilly invested in June 2026 to find clinical trial patients in doctor visits.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Equity
Flexible Spending (FSA) & Health Savings (HSA) Accounts
Learning and Development budget
401k Plan
Paid Parental Leave
Flexible working hours
Home Office Budget
Sabbatical Leave
Growth & Insights and Company News
6 month growth
2%1 year growth
4%2 year growth
4%Now in Practice: September 2026. Welcome back to Now in Practice. One throughline in this month's release is the timing and detail behind how complex care makes it into the record. Diagnoses organized and refined while the clinician is still in the note. Related conditions grouped together so combination codes can surface before the chart closes. Cues that capture what was discussed during an inpatient stay while the story is still fresh. So much of what often comes back weeks later as a retrospective query was known in the moment, and each of these updates is a version of the same goal: settling that detail at the point of care so the record reflects the full complexity of the care delivered and holds up on review. Alongside them, two updates give administrators more direct control over their Abridge implementation, and two specialty model enhancements now capture the details that define allergy and palliative care. Closing CDI gaps before the chart reaches coding. Three capabilities in this release are focused on closing the gap between the care delivered and the care that is documented: the diagnosis that's accurate but not specific enough, the combination code split across a flat list, and the observation made at the bedside that never reaches the note. This builds on Abridge's Query Engine, introduced in July, which surfaces AAPC-compliant CDI queries inline in the note when a documentation gap is present. This month extends the same idea to the diagnosis list itself and to the smaller details of an inpatient stay, where a formal query would be heavier than the detail warrants. Visit Dx integration enhancements. Its Visit Dx integration now brings problem headers, diagnosis search, and specificity options together in a single place, within the documentation workflow. Diagnoses can be organized under the right headers, found or replaced inline, and refined to a more specific option when the modifier detail is available, all without stepping out of the note. The goal is an accurate diagnosis list that's settled during documentation, rather than days or weeks later when a review or query flags what's missing. Problem grouping. Abridge now groups related diagnoses on the problem list into logical clusters, organized the way clinicians reason about a patient rather than as a flat list. With related conditions side by side, combination codes are easier to spot for review while the clinician is still in the note. A combination code split across a flat list is exactly the kind of gap retrospective review exists to reconstruct; catching it at the source means the case mix reflects the complexity of the patients actually treated. Query Engine: inpatient cues. While clinicians chart an inpatient stay, Abridge now surfaces non-blocking cues that point to care already discussed or assessed: whether wounds were present when skin integrity was checked on admission, or the key decisions from a goals-of-care conversation. Each cue carries its supporting evidence and can be acted on or dismissed in one step. Because the prompt arrives while the context is still fresh, the full complexity of the care makes it into the chart, and clinicians can have more confidence that nothing was left out. Cued, not interrupted. The instinct with any documentation prompt is to make it impossible to ignore. But a prompt that blocks signature teaches clinicians to click through it, and once that habit forms, the prompts that matter get the same treatment as the ones that don't. Cues are dismissible because the clinician is the one who knows whether a detail belongs in the record, which is also what makes every acted-on cue meaningful. More control for the teams running Abridge. As implementations scale across care settings, it becomes more important than ever for the teams administering Abridge to be able to manage access on their own timeline and verify the work the platform does on their behalf. Two updates this month give project and CDI teams more direct control over their Abridge implementation. Self-Serve user management. Partners can now add, edit, and remove user access directly from the Enterprise Portal, with users across surfaces visible in one place. For Abridge Inside, an optional approval queue routes clinician access requests to admins to approve or deny, replacing manual updates to the Epic Ambient Allowlist for organizations looking to centralize Abridge access. Every hire, role change, and departure can be handled as it happens. It's a direct response to partner feedback: the time between a staffing change and a clinician's working account shouldn't depend on someone else's queue. QA Viewer for Query Engine logs. CDI teams can now open any Query Engine query in the QA Viewer and see its full record alongside the clinical note: the documentation gap it surfaced, the evidence behind it, the compliance rationale, and how the clinician responded. Instead of re-checking every query by hand, reviewers can spot-check the engine's judgment case by case and build confidence in the routine layer of query work, so their time goes to the complex cases that need real judgment. Deeper detail for specialty care. Every specialty has terminology and details that a general note structure may not be tuned to surface. Two recent note enhancements capture what matters most in allergy/immunology and palliative care. Allergy/Immunology model enhancement. Allergy/Immunology notes now record allergens, triggers, and reaction timelines exactly as discussed, so a peanut allergy stays a peanut allergy. The HPI captures medications by name, dose, and device along with prior skin prick and IgE results, and the plan carries immunotherapy schedules and dosing. In allergy care, the specific allergen and the timing of a reaction are the clinical picture, and the note should carry them that way. Palliative model enhancement. The palliative note now generates a dedicated Goals of Care subsection in the HPI, with a corresponding summary of action steps in the Assessment & Plan. The note also improves capture of medication dosages and changes, including MEDD and pain pump settings, along with palliative-specific scores like the Palliative Performance Scale (PPS). Goals-of-care conversations are often the most consequential part of a palliative visit, and they deserve a place in the note that matches their weight. This month's release is about the record keeping pace with the care. A diagnosis is refined before the note is signed, a combination code surfaces while the clinician can still act on it, and what was observed at the bedside reaches the chart while the story is fresh. Behind the note, admins manage access on their own timeline and CDI teams can see exactly why each query was raised. That's what Abridge shipped in September, and Abridge'd love to have you see it in practice.
Abridge, Free Market Health reflect on growth at life sciences summit. Abridge and Free Market Health, both Pittsburgh-based, closed out Wednesday's Bio + Health Summit hosted by the Pittsburgh Life Sciences Alliance. Reba Schenk, Abridge's vice president of partner experience, and Joe Cardosi, CEO of Free Market Health, both spoke during a Bio + Health Summit panel titled "Growth Stage Lessons" that was moderated by Patrick Colletti, CEO of CoSage. Abridge, founded in 2018 in Pittsburgh, uses generative AI to transcribe doctor-patient conversations. Considered one of Pittsburgh's "Unicorns," it collaborates with over 300 U.S. health systems. Free Market Health, established in 2019, connects insurance providers with specialty drug pharmacies. It manages $15 billion in annual specialty medication spend and serves 11 million patients. Both companies have impressive portfolios, but Schenk and Cardosi noted that they've had some growing pains along the way, while also making significant gains in their fields. Schenk, who joined Abridge in 2024, explained that initially their company started as a patient-facing app. Eventually, Abridge learned that the clinicians they worked with did not like the idea of patients recording their visits. Abridge pivoted and since then has continued to improve its services. Schenk said that the day she realized the scale of Abridge's impact was when the company ran out of compute capacity for its services. "The early days were full of technical challenges like that, and also human challenges of taking these personal relationships that our CEO had built, that were tech friends of his, and scaling that authenticity because we're so passionate about human connection in healthcare," Schenk said. "Figuring out how to scale both the technology and the human side of it that quickly, when we had 10 major health systems at one point going live a week, is truly unprecedented for what I've seen in healthcare." In recent years, Abridge has expanded its footprint to San Francisco and New York, and initiated partnerships with other major companies like Nvidia and Eli Lilly. Over the years, Abridge has also seen significant growth in its staffing numbers. Schenk said that when she first started with the company, there were around 60 people within the company and now it has expanded to over 600. The mission to help people is something that really drives workers at Abridge, according to Schenk. But she noted that sometimes it becomes hard to translate that mission. "We wanted to build very thoughtful experiences for our customers, so we have to be intentional about that, and we have to encourage each other and set the standards," she said. "But I think it is also about taking the time for human connection internally. We had someone who was one of the first people who departed our team a couple of weeks ago, and I chatted with her before she left. And one of the things she told me that was hard to hear is that she felt disconnected. And it was a good reminder to me that it's not just about connecting with our customers; it's about connecting with each other and taking the time to remind each other why we're doing the work." Cardosi, when reflecting on Free Market Health's first days, said that it took them a while to "crack the code" of what they were doing. He said the impact became clear only when they began expanding into Pennsylvania and states like North Carolina. Cardosi said that they're working to expedite the specialty drug process for patients, acknowledging that they're sometimes forgotten about during the pharmaceutical process. "Let's get the medication to the patient as fast as humanly possible and make sure it's a high-quality pharmacy," he said. "We're building the things, whether that's features, capabilities, integrations, to get in that moment as often as possible, as early as possible, and to make that connection to a high-quality pharmacy happen as seamlessly, systematically as possible, so the patients don't have to be the advocates for their care." Free Market Health has partnered with other organizations like Highmark's specialty pharmacy, which has helped ease the process for patients. Cardosi emphasized that their overall goal is to help people and improve their experience in the healthcare system. "I think we want to make an actual impact. Maybe a logo or something on a building will be an indicator or signal that we're making an impact, but for us, that's already helping patients, people in their most vulnerable times," he said. "We have a super compelling opportunity to make an impact on people in really tough times in their lives by showing up as a technology company and helping the thing that's hard for them today be a little bit easier." Read the full story from from Pittsburgh Business Times.
AI model costs are pushing startups towards cheaper open weigh. Harvey's gross margin fell to minus 50% by June before it built a model of its own on a Chinese base, and Mistral's chief executive spent July warning European buyers that this is what renting a closed model does to you September 21, 2026 - 5:30 pm Harvey's gross margin fell from about 50% at the start of this year to minus 50% by June as customer usage of its AI agents spiked, and turned positive again only after it released a model of its own built on Moonshot's Kimi K3. Abridge, Decagon, Ramp and Rogo are making similar moves, and Sequoia Capital and General Catalyst are funding the shift. Harvey's gross margin fell from about 50% at the start of this year to minus 50% by June, Bloomberg reported, citing a person familiar with the matter. The legal startup is valued at $15.6B. Customer usage had spiked after a March update to its AI agents. The cost was the models it rented. Harvey has seen a twentyfold rise in token usage this year, according to the company. Both OpenAI and Anthropic now charge enterprises for model usage on top of base subscription fees. Its founders knew the spike would not survive contact with those rates. So it stopped renting. In August Harvey released its first in-house model, post-trained on Kimi K3 from the Chinese lab Moonshot. Gross margins turned positive again after that launch and other changes to how it uses AI, people familiar with the work told Bloomberg. Harvey declined to comment on specific financials. It is not alone. Abridge is building a clinical model on Nvidia's open weights, and Decagon now routes 80% of customer queries through models of its own. Ramp raised $750M in June and is weighing training for the first time. "It made absolutely no sense a year ago," co-chief executive Karim Atiyeh said. "It's starting to make a lot more sense now." Anthropic has noticed. At an investor forum in its offices it showed a slide on startups building their own models, with a reminder that Harvey still needs Opus for its hardest tasks. Mistral's Arthur Mensch spent July arguing that closed models give providers immense leverage, and named Anthropic cutting off Windsurf while building Claude Code. September made his case for him. OpenAI moved to end its Cursor contract after SpaceX bought the company, citing past terms of service breaches by Musk businesses. European buyers have switching rights under the Data Act, but those cover a customer leaving a supplier, not a supplier leaving a customer. Europe has its own Harvey. Legora, in Stockholm, reached $100M in revenue inside 18 months and now serves more than 1,200 firms, and it has never said whose models it runs on. Not everyone thinks the answer matters. "Having your own model or not is such the wrong question," said Menlo Ventures partner Matt Kraning. "In most cases, it tends to be a lot of cosplay."
Abridge announced a pre-bill review capability for clinical documentation integrity (CDI), coding, and revenue cycle teams. The feature reviews inpatient claims before submission, comparing final coded diagnoses and diagnosis-related groups (DRG) against clinical documentation. The platform identifies discrepancies and provides supporting evidence, allowing teams to resolve issues before claims become denials. Abridge does not alter documentation, codes, or claim status—CDI teams retain control over holding, correcting, or releasing claims. The capability builds on Abridge's existing clinician intelligence platform, which captures records during clinical interactions. By extending this platform into pre-bill review, Abridge enables comparison between clinical records and claim diagnoses before submission. This approach aims to ensure coded records accurately reflect the documented complexity of care, addressing the gap between care delivery and reimbursement.
Top Pharma news: July 2026. Posts You Might Like What were the top pharma news stories as of July 2026? July's pharmaceutical landscape was shaped by continued U.S. drug pricing reform, a breakthrough in cancer treatment innovation, and expanding investment in artificial intelligence across healthcare. The Trump administration moved to strengthen Medicare drug pricing regulations, China approved the world's first CAR-T therapy for solid tumors, and leading healthcare organizations accelerated AI adoption to improve drug development, clinical decision-making, and specialty pharmacy services. The Fullintel Hub keeps stakeholders informed as these developments unfold. June 2026 Pharma news breakdown. What does the proposed CMS rule signal about the administration's drug pricing strategy? The Trump administration proposed a comprehensive rule through the Centers for Medicare and Medicaid Services to codify federal Medicare drug price negotiations permanently. This measure closes a major regulatory loophole that previously allowed pharmaceutical companies to avoid mandated price caps simply by adding active ingredients or slightly reformulating existing single-source medications. What it means: * The proposal strengthens the long-term stability of Medicare drug price negotiations by reducing opportunities for legal or regulatory challenges. * Drug manufacturers may face increased pressure to align pricing strategies with negotiated Medicare prices, closing off traditional product-hopping workarounds. * The move reinforces drug affordability as a central healthcare policy priority while increasing scrutiny of pharmaceutical pricing practices. Social media sentiment was generally positive, with "Love" and "Wow" reactions reflecting support for closing corporate loopholes and reducing out-of-pocket prescription costs for seniors. Limited negative sentiment likely reflected skepticism over whether drugmakers might find new regulatory workarounds or reduce overall investment in drug discovery. Why is CARsgen's approval considered a milestone? China approved CARsgen Therapeutics' satricabtagene autoleucel, making it the world's first CAR-T therapy approved for treating solid tumors. The therapy targets Claudin18.2-positive gastric and gastroesophageal junction cancers, representing a major scientific breakthrough after years of limited success applying CAR-T technology beyond blood cancers. What it means: * The approval establishes proof of concept for CAR-T therapies in solid tumors, addressing one of oncology's biggest unmet challenges. * China continues strengthening its position as a global leader in advanced cell and gene therapy innovation, raising questions about when Western regulatory bodies like the U.S. FDA will follow. * The decision is expected to accelerate investment in next-generation CAR-T platforms targeting additional solid tumor indications, opening doors for broader commercial applications in hard-to-treat cancers. Social media sentiment was generally positive, with dominant "Love" and "Wow" reactions reflecting support for lower out-of-pocket drug costs and innovative medicine. The pulse: AI in healthcare. 1. Nvidia, Abridge collaborate to develop healthcare-specific AI model. Nvidia and healthcare AI company Abridge announced a collaboration to develop healthcare-specific foundation models designed to improve clinical documentation, physician workflows, and medical decision support. The partnership combines Nvidia's AI infrastructure with Abridge's expertise in clinical language models to expand generative AI adoption across healthcare systems. * Coverage Sentiment: Positive. Analysts view the partnership as another major step toward specialized AI models built specifically for healthcare applications. * Dominant Social Sentiment: "Wow" - Healthcare technology communities praised the collaboration for addressing clinician burnout while improving documentation accuracy. * News Source: Fierce Healthcare 2. Cigna invests $100M in new ai-powered specialty pharmacy program. Cigna announced a $100M investment to launch a new AI-powered specialty pharmacy program designed to improve patient support, streamline prior authorization processes, and optimize medication management for complex diseases. * Coverage Sentiment: Positive. Coverage emphasized operational efficiency and improved patient engagement through AI-enabled pharmacy services. * Dominant Social Sentiment: "Love" - Discussion focused on AI's potential to simplify specialty pharmacy experiences while reducing administrative burdens. * News Source: Reuters 3. AstraZeneca CEO says AI is reshaping drug development and helping boost the odds of success. AstraZeneca CEO Pascal Soriot stated that artificial intelligence is significantly improving the probability of success throughout the drug discovery and development process. AI is increasingly being integrated into target identification, clinical trial design, and molecule optimization to accelerate research while reducing development costs. * Coverage Sentiment: Positive. Industry observers increasingly view AI as a competitive advantage for pharmaceutical R&D. * Dominant Social Sentiment: "Wow" - Conversations centered on AI's growing role in transforming pharmaceutical innovation and improving research productivity. * News Source: CNBC Key pharmaceutical industry takeaways for July 2026. What do these developments signal for the health and life sciences industry? * Medicare drug pricing reform continues to evolve, with policymakers focusing on strengthening the regulatory framework supporting negotiated drug prices. * Cell therapy innovation has entered a new phase as CAR-T technology expands beyond blood cancers into solid tumor treatment. * AI investment is accelerating across the healthcare ecosystem, extending beyond research into clinical operations, pharmacy services, and physician workflows. * Specialized healthcare AI models are emerging as the preferred strategy for improving clinical accuracy and operational efficiency. * Global competition in pharmaceutical innovation continues to intensify, with China demonstrating increasing leadership in advanced oncology therapies. About Fullintel's pharmaceutical news Coverage. The Fullintel Hub delivers daily pharmaceutical news analysis and insights to support PR and communications teams. Its human analysts track key developments across traditional media, social platforms, and industry publications. Its award-winning methodology, including its proprietary Media Impact Score and Trust Score, helps organizations refine messaging and benchmark against competitors. About Fullintel Strategic Media Analysis. Fullintel's Strategic Media Analysis measures the true impact of PR and communications efforts for pharmaceutical and healthcare organizations. Angela Dwyer, VP of Insights, leads its pharmaceutical analysis practice. Her original trust factor research has been presented at PRSA ICON and IPR conferences, and she has been named a PRNEWS Top Women Award recipient and 2025 AMEC Award winner. Angela Dwyer. Angela is VP of Insights at Fullintel - a media intelligence company that specializes in news monitoring and analysis. She has worked in media measurement for 15 years, helping brands improve business results through data-driven, actionable insights. From public relations agencies like Lippe Taylor to media research firms like PRIME Research, she has consulted across industries, particularly healthcare and pharmaceuticals. She has presented and published several award-winning research papers about news content that drives recall, engagement, and brand trust. Her "Trust in Pharma" research outlines how biopharma brands can build and sustain trust. She contributes knowledge at the intersection of academia and practice as director of the International Public Relations Measurement Commission and as a member of the International Public Relations Research Conference Board. Her contributions have been recognized with multiple industry awards, including PRNEWS People of the Year (Data & Measurement Game Changer), PRNEWS Top Women (Industry Champions), and AMEC Rising Star for innovation in communication measurement. Learn more about Angela Dwyer's expertise, industry recognition, and thought leadership.